Adult stem cell products could be lining up to penetrate the inflammation and orthopedics markets, judging by the recent $1.38 billion paid by Genzyme for Osiris's mesenchymal stem cell technology.

Genzyme Corp. (Sanofi Genzyme) has divulged emopamil-binding protein (EBP) inhibitors reported to be useful for the treatment of multiple sclerosis, transverse myelitis, neuromyelitis optica, optic ...

The company remains convinced of the product's merits and—bolstered by the backing of a $1.38 billion deal from Genzyme a year ago—continues to pursue cardiac and other autoimmune indications.

Chesbrough, Henry W., and Clarissa Ceruti. "Genzyme: Engineering the Market for Orphan Drugs." Harvard Business School Case 602-147, March 2002. (Revised May 2002.) ...

Genzyme said in a Sanofi statement it had received an FDA 'complete response letter', to which it would appeal. Its president and chief executive was " extremely disappointed with the outcome of ...

Sanofi has settled a long-running dispute with shareholders in the biotech Genzyme, who claimed the big pharma deliberately held back development of a multiple sclerosis drug to avoid payments ...